Syquant Capital’s Intra-Cellular Therapies ITCI Stock Holding History
Bought
Maintained
Sold
Other funds holding ITCI
Syquant Capital's ITCI Position: Q2 2025 in Review
Syquant Capital sold out of Intra-Cellular Therapies (ITCI) in Q2 2025, closing a stake of 266,228 shares — an estimated $35.1M sold.
Syquant Capital first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $35.1M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Syquant Capital reported no remaining Intra-Cellular Therapies position as of Q2 2025 after selling out during the quarter.
- Syquant Capital sold 266,228 Intra-Cellular Therapies shares in Q2 2025, an estimated $35.1M.
- Syquant Capital first reported a position in Intra-Cellular Therapies in Q1 2025 and held it in 1 quarter.
- Syquant Capital's Intra-Cellular Therapies position peaked at $35.1M in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies as of Q2 2025.
Based on Syquant Capital's 13F filing for Q2 2025, filed 15 Jul 2025.